• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OncoSec Medical Incorporated

    5/25/23 4:13:04 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ONCS alert in real time by email
    SC 13G 1 ea179182-13gintra_oncosec.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.  )*

     

    OncoSec Medical Incorporated

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share 

     

    (Title of Class of Securities)

     

    68234L405

    (CUSIP Number)

     

    May 16, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐  Rule 13d-1(b)
    b. ☒  Rule 13d-1(c)
    c. ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 7

     

     

    CUSIP No.

    68234L405

     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
     
    5.  Sole Voting Power    0
     
     
    6.  Shared Voting Power    313,158
     
     
    7.  Sole Dispositive Power    0
     
     
    8.  Shared Dispositive Power    313,158
     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    313,158 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
       
    11. Percent of Class Represented by Amount in Row (9)    4.99% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 7

     

     

    CUSIP No. 68234L405  

     

    1. Names of Reporting Persons.
       
     

    Daniel B. Asher

       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
     
    5.  Sole Voting Power    0
     
     
    6.  Shared Voting Power    313,158
     
     
    7.  Sole Dispositive Power    0
     
     
    8.  Shared Dispositive Power    313,158
     
       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    313,158 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
       
    11. Percent of Class Represented by Amount in Row (9)    4.99% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 3 of 7

     

     

    CUSIP No. 68234L405  

     

    1. Names of Reporting Persons.
       
     

    Intracoastal Capital LLC

       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     Delaware
       
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
     
    5.  Sole Voting Power    0
     
     
    6.  Shared Voting Power    313,158
     
     
    7.  Sole Dispositive Power    0
     
     
    8.  Shared Dispositive Power    313,158
     
       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    313,158 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)    4.99% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

    Page 4 of 7

     

     

    Item 1.

     

    (a)Name of Issuer

     

    OncoSec Medical Incorporated (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    820 Bear Tavern Road

    Ewing, New Jersey 08628

     

    Item 2.

     

    (a)Name of Person Filing
    (b)Address of Principal Business Office or, if none, Residence
    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common Stock, $ 0.0001 par value per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    68234L405

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i)       Immediately following the execution of the Securities Purchase Agreement with the Issuer on May 16, 2023 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on May 18, 2023), each of the Reporting Persons may have been deemed to have beneficial ownership of 264,551 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 5.5% of the Common Stock, based on (1) 4,554,178 shares of Common Stock outstanding as of May 16, 2023, as reported by the Issuer, plus (2) 264,551 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 264,551 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 80,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 609,102 shares of Common Stock.

     

    Page 5 of 7

     

     

    (ii)       As of the close of business May 25, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 313,158 shares of Common Stock, which consisted of (i) 264,551 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (ii) 48,607 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 4,554,178 shares of Common Stock outstanding as of May 16, 2023, plus (2) 1,408,384 shares of Common Stock in the aggregate issued at the closing of the transaction contemplated by the SPA, (3) 264,551 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (4) 48,607 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 31,393 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 344,551 shares of Common Stock.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:        0        .

     

    (ii) Shared power to vote or to direct the vote: 313,158.

     

    (iii) Sole power to dispose or to direct the disposition of        0         .

     

    (iv) Shared power to dispose or to direct the disposition of 313,158.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 25, 2023

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 7 of 7

     

    Get the next $ONCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    EWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules. The Company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,408,384 shares of common stock. The warrants have an exercise price of $0.82 per sh

    5/18/23 4:30:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of  an aggregate of 1,408,384 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.945 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent

    5/16/23 1:29:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

    EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12

    5/16/23 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Delaversano Robert J sold $55 worth of shares (40 units at $1.37), decreasing direct ownership by 4% to 1,008 units (withholding obligation)

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    2/9/23 8:11:50 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4: Delaversano Robert J sold $105 worth of shares (283 units at $0.37), decreasing direct ownership by 1% to 22,975 units (tax withholding)

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    11/4/22 8:21:02 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Foster Spahr Stephany

    4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)

    10/12/22 3:49:42 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on OncoSec Medical with a new price target

    BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00

    3/15/21 8:10:02 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BTIG Research initiated coverage on OncoSec Medical with a new price target

    BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00

    3/8/21 6:47:53 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    SEC Filings

    View All

    SEC Form 25-NSE filed by OncoSec Medical Incorporated

    25-NSE - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    7/10/23 6:08:05 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Medical Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)

    6/22/23 8:30:17 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Medical Incorporated filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update

    8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)

    6/14/23 5:20:09 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Financials

    Live finance-specific insights

    View All

    OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

    PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled meta

    11/2/21 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OncoSec Medical Incorporated (Amendment)

    SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    2/13/24 2:30:19 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by OncoSec Medical Incorporated

    SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    5/25/23 4:13:04 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by OncoSec Medical Incorporated

    SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)

    5/19/23 2:57:56 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ONCS
    Leadership Updates

    Live Leadership Updates

    View All

    OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

    PENNINGTON, N.J. and SAN DIEGO, April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer. Dr. Arch was previously Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021, and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Robert's leadership roles have been focused on shaping strong teams and b

    4/29/22 8:00:00 AM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Announces Appointment of George Chi as Chief Financial Officer

    PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer. Mr. Chi joins the Company from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the company's plasma collection business and establish regular commercial sales. Prior to joining THPlasma, Mr. Chi served as Chief Financial Officer of CASI Pharmaceuticals, Inc. ("CASI"), a biopharmaceutical company

    2/22/22 5:59:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

    PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.  Mr. O' Connor is also stepping down from his seat on the Board of Directors.   "Under Dan's leadership over the past four years, OncoSec has transformed itself into the leading intra-tumoral cancer immunotherapy Company," said Margaret Dalesandro, Ph.D., Chair of the Board of Directors at OncoSec.  "Dan operationally drove several value-creating clinical programs with the Comp

    6/24/21 4:30:00 PM ET
    $ONCS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care